AWS
SLDB icon

Atria Wealth Solutions’s Solid Biosciences SLDB Stock Holding History

Atria Wealth Solutions’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,617
Closed -$33K – 1844
2022
Q2 		$33K Buy
+3,617
New +$37.6K ﹤0.01% 1598

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Atria Wealth Solutions's SLDB Position: Q3 2022 in Review

Atria Wealth Solutions sold out of Solid Biosciences (SLDB) in Q3 2022, closing a stake of 3,617 shares — an estimated $33K sold.

Atria Wealth Solutions first reported a position in SLDB in Q2 2022 and held it in 1 quarter. The position peaked at $33K in Q2 2022. 58 funds tracked by Wall St. Rank hold SLDB as of Q3 2022.

  • Atria Wealth Solutions reported no remaining Solid Biosciences position as of Q3 2022 after selling out during the quarter.
  • Atria Wealth Solutions sold 3,617 Solid Biosciences shares in Q3 2022, an estimated $33K.
  • Atria Wealth Solutions first reported a position in Solid Biosciences in Q2 2022 and held it in 1 quarter.
  • Atria Wealth Solutions's Solid Biosciences position peaked at $33K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2022.

Based on Atria Wealth Solutions's 13F filing for Q3 2022, filed 14 Nov 2022.